FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Mar 25, 2026
Nkarta, Inc. (NKTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $104.1 million. Free cash flow was -$89.9 million. As of Jun 30, 2026 it held $240.4 million in cash and investments and $73.5 million in total debt.
Revenue
$0
Net income
$-104.08M
+4.3% vs prior year
Operating cash flow (TTM)
$-92.76M
+5.0% vs year-ago TTM
Free cash flow (TTM)
$-93.90M
+6.3% vs year-ago TTM
EPS
$-1.41
+11.9% vs prior year
Dividend per share
$0.00
Shares outstanding
71.29M
+0.5% vs prior year
Net cash
$166.90M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NKTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1787400
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — |
| Operating income | -$122.0M | -$128.2M | -$131.7M | -$119.0M | -$86.4M |
| Net income | -$104.1M | -$108.8M | -$117.5M | -$113.8M | -$86.1M |
| Diluted EPS | -$1.41 | -$1.60 | -$2.40 | -$2.61 | — |
| Operating cash flow | -$88.7M | -$99.7M | -$86.2M | -$57.0M | -$67.9M |
| Free cash flow | -$89.9M | -$104.1M | -$114.3M | -$104.1M | -$73.0M |
| Total assets | $404.2M | $501.2M | $378.9M | $472.9M | $273.9M |
| Total liabilities | $91.9M | $93.2M | $105.6M | $100.7M | $22.9M |
| Stockholders' equity | $312.3M | $408.0M | $273.3M | $372.2M | $251.0M |
| Cash and investments | $292.4M | $377.7M | $248.2M | $352.1M | $238.1M |
| Total debt | $76.4M | $80.3M | $88.3M | $82.9M | $12.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 10, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
| ARS | Annual report to shareholders | Apr 23, 2026 | Dec 31, 2025 |
All 436 Nkarta, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.